WO1996023071A3 - MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY - Google Patents

MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY Download PDF

Info

Publication number
WO1996023071A3
WO1996023071A3 PCT/US1996/001119 US9601119W WO9623071A3 WO 1996023071 A3 WO1996023071 A3 WO 1996023071A3 US 9601119 W US9601119 W US 9601119W WO 9623071 A3 WO9623071 A3 WO 9623071A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
bind
monoclonal antibodies
epitopes
present
Prior art date
Application number
PCT/US1996/001119
Other languages
French (fr)
Other versions
WO1996023071A9 (en
WO1996023071A2 (en
Inventor
Anthony W Siadak
Diane Hollenbaugh
Lisa K Gilliland
Marcia L Gordon
Jurgen Bajorath
Alejandro A Aruffo
Linda J Harris
Original Assignee
Bristol Myers Squibb Co
Anthony W Siadak
Diane Hollenbaugh
Lisa K Gilliland
Marcia L Gordon
Jurgen Bajorath
Alejandro A Aruffo
Linda J Harris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL11688296A priority Critical patent/IL116882A/en
Priority to EP96906207A priority patent/EP0807175A2/en
Priority to PL96323565A priority patent/PL182868B1/en
Priority to AU49669/96A priority patent/AU692074B2/en
Priority to CZ972339A priority patent/CZ233997A3/en
Priority to JP8523029A priority patent/JPH10513348A/en
Application filed by Bristol Myers Squibb Co, Anthony W Siadak, Diane Hollenbaugh, Lisa K Gilliland, Marcia L Gordon, Jurgen Bajorath, Alejandro A Aruffo, Linda J Harris filed Critical Bristol Myers Squibb Co
Priority to MX9705610A priority patent/MX9705610A/en
Priority to NZ303375A priority patent/NZ303375A/en
Publication of WO1996023071A2 publication Critical patent/WO1996023071A2/en
Publication of WO1996023071A3 publication Critical patent/WO1996023071A3/en
Publication of WO1996023071A9 publication Critical patent/WO1996023071A9/en
Priority to FI973120A priority patent/FI973120A/en
Priority to NO973447A priority patent/NO973447L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides monoclonal antibodies, antigen binding fragment and recombinant binding proteins specific for human gp39. These antibodies are specific for at least 12 different epitopes on gp39. Hybridomas secreting specific antibodies which bind to these epitopes are also provided. Further, the present invention discloses the amino acid sequence of immunoglobulin light and heavy chain variable regions which bind to epitopes of gp39 and provide sFv and humanized antibodies which bind gp39. Also, provided are pharmaceutical compositions comprising the monoclonal antibodies, antigen binding fragments and recombinant binding proteins which bind gp39 and methods for using these compositions in diagnosing disease states, inhibiting B cell activation and for treating immunological disorders, such as autoimmune diseases, allergic responses, organ rejection and graft-versus-host disease. Antibodies of the present invention can also be used to image cells which express gp39 on their surface, such as tumor cells (e.g., lymphoma) and to target therapeutic agents to target cells.
PCT/US1996/001119 1995-01-26 1996-01-26 MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY WO1996023071A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL11688296A IL116882A (en) 1995-01-26 1996-01-24 Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy
PL96323565A PL182868B1 (en) 1995-01-26 1996-01-26 Monoclonal antibodies specific for various epitopes of human gp39 as well as methods of using them in diagnosis and therapy
AU49669/96A AU692074B2 (en) 1995-01-26 1996-01-26 Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
CZ972339A CZ233997A3 (en) 1995-01-26 1996-01-26 MONOCLONAL ANTIBODIES AGAINST VARIOUS EPITOPES OF HUMAN pg39 AND METHODS OF THEIR USE IN DIAGNOSIS AND THERAPY
JP8523029A JPH10513348A (en) 1995-01-26 1996-01-26 Monoclonal antibodies specific for various epitopes of human gp39 and their use in diagnosis and therapy
EP96906207A EP0807175A2 (en) 1995-01-26 1996-01-26 MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY
MX9705610A MX9705610A (en) 1995-01-26 1996-01-26 MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY.
NZ303375A NZ303375A (en) 1995-01-26 1996-01-26 Monoclonal antibodies specific for different epitopes of human gp39 and diagnostic and therapeutic methods using them
FI973120A FI973120A (en) 1995-01-26 1997-07-25 Monoclonal antibodies specific for various epitopes of human gp39 and methods for their use in diagnosis and therapy
NO973447A NO973447L (en) 1995-01-26 1997-07-25 Monoclonal antibodies specific for different epitopes in human gp 39, and methods for their use in diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/379,057 US5876950A (en) 1995-01-26 1995-01-26 Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US08/379,057 1995-01-26

Publications (3)

Publication Number Publication Date
WO1996023071A2 WO1996023071A2 (en) 1996-08-01
WO1996023071A3 true WO1996023071A3 (en) 1996-09-26
WO1996023071A9 WO1996023071A9 (en) 1996-11-28

Family

ID=23495642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/001119 WO1996023071A2 (en) 1995-01-26 1996-01-26 MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY

Country Status (15)

Country Link
US (1) US5876950A (en)
EP (2) EP1728864B1 (en)
JP (1) JPH10513348A (en)
AU (1) AU692074B2 (en)
CA (1) CA2210419A1 (en)
CZ (1) CZ233997A3 (en)
ES (1) ES2391101T3 (en)
FI (1) FI973120A (en)
HU (1) HUP9802401A3 (en)
IL (1) IL116882A (en)
MX (1) MX9705610A (en)
NO (1) NO973447L (en)
NZ (1) NZ303375A (en)
PL (1) PL182868B1 (en)
WO (1) WO1996023071A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
EA200501076A1 (en) * 1997-01-10 2006-06-30 Байоджен Айдек Ма Инк. TREATMENT OF VARIETY JADE WITH THE USE OF ANTI-CD40L COMPOUNDS
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
WO1998058678A1 (en) * 1997-06-20 1998-12-30 Tanox Pharma B.V. Anti-cd40l immunotoxins for the treatment of diseases
EP1754490A3 (en) 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
EP1067954A4 (en) * 1998-04-03 2004-08-18 Dartmouth College USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE
ES2246093T3 (en) * 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. MOLECULAR PATHOGENICIDE THAT INDUCES A RESISTANCE TO DISEASE IN PLANTS.
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
FR2798386B1 (en) 1999-09-10 2003-04-25 Didier Raoult SINGLE-STRANDED OLIGONUCLEOTIDES, PROBES, PRIMERS AND METHOD FOR DETECTION OF SPIROCHETS
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
DE19962583A1 (en) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad New antibodies specific for plasma cells, useful for treatment and diagnosis of autoimmune diseases and plasma cell tumors
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CN1441675A (en) 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 Compositions and methods for achieving immune suppression
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2001273174B2 (en) 2000-07-03 2006-05-18 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble CTLA4 molecule
JP2004525605A (en) * 2000-08-04 2004-08-26 ルードヴィヒ インスティテュート フォー キャンサー リサーチ Suppressor gene
AU2001287040A1 (en) * 2000-09-01 2002-03-13 Biogen, Inc. Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002241922B2 (en) * 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
AU2002305716B2 (en) 2001-05-23 2007-10-25 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
PT1517921E (en) * 2002-06-28 2006-09-29 Domantis Ltd DIFFERENTLY SPECIFIED LIGANDS WITH SEMI-LIFE IN THE INCREASED SERUM
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
ES2557325T5 (en) 2004-12-28 2023-11-15 Innate Pharma Sa Monoclonal antibodies against NKG2A
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
DK3056568T3 (en) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
CN101500608A (en) 2006-06-08 2009-08-05 中外制药株式会社 Preventive or remedy for inflammatory disease
JP2009539413A (en) * 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Single-chain multivalent binding protein with effector function
RU2499001C2 (en) * 2006-06-30 2013-11-20 Ново Нордиск А/С Antibodies to nkg2a and their applications
EP2311481A3 (en) 2006-10-20 2013-10-16 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
CN103408661B (en) * 2007-01-05 2016-04-06 苏黎世大学 The method of disease-specific binding molecules and target is provided
CL2008002886A1 (en) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
EP2247619A1 (en) 2008-01-24 2010-11-10 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
ES2368700T3 (en) * 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc IMMUNOTHERAPEUTIC AGENT FOR CD37 AND COMBINATION WITH A BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT OF THE SAME.
KR102469853B1 (en) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
HUE028589T2 (en) * 2008-07-10 2016-12-28 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
CA2737351A1 (en) * 2008-09-26 2010-04-01 Wyeth Llc Single chain antibody library design
JP2012511014A (en) 2008-12-05 2012-05-17 エイエルエス・セラピー・デベロップメント・インスティテュート Methods for treating neurodegenerative diseases
JP5139517B2 (en) * 2008-12-05 2013-02-06 中外製薬株式会社 Anti-NR10 antibody and use thereof
KR20160062207A (en) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
JP2010210772A (en) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
JP5787446B2 (en) 2009-03-19 2015-09-30 中外製薬株式会社 Antibody constant region variants
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012158948A1 (en) 2011-05-17 2012-11-22 The Rockefeller University Human immunodeficiency virus neutralizing antibodies adn methods of use thereof
AU2012268939B2 (en) 2011-06-17 2017-05-04 Novo Nordisk A/S Selective elimination of erosive cells
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
AR088455A1 (en) 2011-10-13 2014-06-11 Bristol Myers Squibb Co ANTIBODIES THAT ANTAGONIZE CD40L
MA41115A (en) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh ALZHEIMER'S DISEASE TREATMENT PROCESS
RU2749512C2 (en) 2015-04-14 2021-06-11 Чугаи Сейяку Кабусики Кайся Pharmaceutical composition for prevention and/or treatment of atopic dermatitis, including il-31 antagonist as the active ingredient
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3 binding polypeptides
EP3565596A4 (en) * 2017-01-05 2020-12-16 Brown University Methods and compositions relating to anti-chi3l1 antibody reagents
JP7263320B2 (en) 2017-08-22 2023-04-24 バイオジェン・エムエイ・インコーポレイテッド Pharmaceutical composition containing anti-beta-amyloid antibody
US10766968B2 (en) 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
CN108484761B (en) * 2018-03-10 2021-04-30 吉林大学 Single-chain antibody for specifically recognizing and inducing depolymerization of oligomer and fibril of Abeta 42, single-chain antibody gene and application thereof
CN110950953B (en) * 2018-09-26 2022-05-13 福州拓新天成生物科技有限公司 Monoclonal antibody against B7-H3 and application thereof in cell therapy
KR102142499B1 (en) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Human monoclonal antibodies targeting YKL-40
WO2021100794A1 (en) 2019-11-20 2021-05-27 中外製薬株式会社 Antibody-containing preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555880A2 (en) * 1992-02-14 1993-08-18 Bristol-Myers Squibb Company The CD40CR receptor and ligands therefor
WO1995006666A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
WO1995006480A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Methods of prolonged suppression of humoral immunity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555880A2 (en) * 1992-02-14 1993-08-18 Bristol-Myers Squibb Company The CD40CR receptor and ligands therefor
WO1995006666A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
WO1995006480A1 (en) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Methods of prolonged suppression of humoral immunity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. ARUFFO ET AL.: "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.", CELL, vol. 72, 29 January 1993 (1993-01-29), CAMBRIDGE, MA, USA, pages 291 - 300, XP002007297 *
D. HOLLENBAUGH ET AL.: "Expression of functional CD40 by vascular endothelial cells.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 182, no. 1, 1 July 1995 (1995-07-01), NEW YORK, NY, USA, pages 33 - 40, XP000574867 *
J. BAJORATH ET AL.: "Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction.", BIOCHEMISTRY, vol. 34, no. 6, 14 February 1995 (1995-02-14), WASHINGTON, DC, USA, pages 1833 - 1844, XP002007296 *
L. RIECHMANN ET AL.: "Reshaping human antibodies for therapy.", NATURE, vol. 332, 24 March 1988 (1988-03-24), LONDON, GB, pages 323 - 327, XP002007298 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant

Also Published As

Publication number Publication date
IL116882A0 (en) 1996-05-14
CZ233997A3 (en) 1997-11-12
EP1728864B1 (en) 2012-08-01
JPH10513348A (en) 1998-12-22
EP1728864A1 (en) 2006-12-06
ES2391101T3 (en) 2012-11-21
PL323565A1 (en) 1998-04-14
FI973120A0 (en) 1997-07-25
NO973447L (en) 1997-09-26
EP0807175A2 (en) 1997-11-19
HUP9802401A3 (en) 2003-03-28
IL116882A (en) 2001-09-13
WO1996023071A2 (en) 1996-08-01
NZ303375A (en) 2000-01-28
AU4966996A (en) 1996-08-14
FI973120A (en) 1997-07-25
US5876950A (en) 1999-03-02
MX9705610A (en) 1997-10-31
HUP9802401A2 (en) 1999-01-28
AU692074B2 (en) 1998-05-28
PL182868B1 (en) 2002-03-29
CA2210419A1 (en) 1996-08-01
NO973447D0 (en) 1997-07-25

Similar Documents

Publication Publication Date Title
WO1996023071A3 (en) MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY
US6572857B1 (en) Anti-CD6 monoclonal antibodies and their uses
DE68925226D1 (en) Monoclonal antibodies
KR960706560A (en) HUMANIZED ANTIBODIES AND USES THEREOF
PT712307E (en) METHODS FOR CONTROL OF THE POPULATION OF CELLS B
KR927003816A (en) Antibody to CD3
RU96115107A (en) "HUMAN" ANTIBODIES AND THEIR USE
EP1798243A3 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
KR960704575A (en) METHODS FOR INDUCING ANTIGEN-SPECIFIC TCELL TOLERANCE
JP2022058881A (en) Clinical assessment of m-protein response in multiple myeloma
DE69535562D1 (en) RECOMBINANT PEPTIDES LEAD FROM THE MC3 ANTIBODY AGAINST BA46, METHODS FOR THEIR USE AND METHOD FOR HUMANIZING ANTIBODY PEPTIDES
Radl Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia).
RU2380377C2 (en) Nogo-A-BINDING MOLECULES AND PHARMACEUTICAL APPLICATION THEREOF
US20110200590A1 (en) Antibodies Directed Against the Myelin Basic Protein Recognising an Epitope of CD64 and Their Use as Immunosuppressants
JP2831852B2 (en) Cell surface proteins expressed on human thymic cortical cells and uses thereof
JPH10509948A (en) Human antibodies to T cell receptor peptides and methods for their preparation
Natvig et al. Partial amino acid sequence analysis and variable subgroup determination (VH and VL) of a monoclonal rheumatoid factor derived from a rheumatoid arthritis patient
JPH06508829A (en) suppressor T cell hybridoma
Ono et al. Monoclonal antibodies to idiotypic determinants on monoclonal rheumatoid factors—application to patients with type II cryoglobulinemia
WO2018005054A1 (en) Monoclonal antibodies targeting killer immunoglobulin-like receptor (kir) family signaling
Riviera et al. Cross-reactivity between thymus surface antigens and human acetylcholine receptor (ACHR)
Morimoto Studies on Highly Sensitive Enzyme Immunoassays by Protein Chemistry
TH13774EX (en) Recombinant antibodies for the treatment of human disease.
GB2286189A (en) Recombinant specific binding protein
RU2000103038A (en) ANCROD-SPECIFIC MONOCLONAL ANTIBODIES, ANTIBODY FRAGMENTS, THEIR MIXTURES OR DERIVATIVES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CZ FI HU JP MX NO NZ PL US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/27-27/27,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 860052

Date of ref document: 19970617

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 303375

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2210419

Country of ref document: CA

Ref country code: CA

Ref document number: 2210419

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PV1997-2339

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/005610

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 973120

Country of ref document: FI

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 523029

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996906207

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1997-2339

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996906207

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1997-2339

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1996906207

Country of ref document: EP